evidence on novel cytokine-modulating strategies in the treatment of moderate to severe psoriasis
Published 3 years ago • 135 plays • Length 28:40Download video MP4
Download video MP3
Similar videos
-
32:26
targeting the burden of moderate to severe psoriasis
-
37:46
the tyk2 pathway as a novel nonbiologic oral therapeutic option in moderate to severe psoriasis
-
34:23
recent advances in the treatment of moderate-to-severe psoriasis: a focus on targeted agents
-
8:37
cytokine imbalance during targeted therapies for psoriasis and atopic dermatitis | francesco messina
-
5:50
psoriasis and beyond: targeting the il-17 pathway
-
5:10
8 strategies to eliminate psoriasis
-
29:55
psoriasis pathogenesis: presenting the key role of keratinocytes
-
6:18
tyk2 inhibitors show efficacy in psoriatic arthritis - medpage today
-
8:10
blocking interleukin-17 in psoriasis: real-world experience from the psoplus cohort | lisa schots
-
1:01
cll resistance mechanisms in the era of novel agents
-
24:51
mapping the path to better patient outcomes in rheumatoid arthritis and psoriatic arthritis
-
26:23
3.3: tnf, il-1, and il-17 family cytokines
-
3:56
ixekizumab, high-affinity il-17a antibody - video abstract 100940
-
34:05
improving outcomes for patients with moderate to severe plaque psoriasis
-
6:36
key cytokines - ra, jia, psoriasis, eczema
-
3:22
introduction to novel treatments
-
19:57
advances in anti-cytokine therapy: new pathways (il 12/23, il17, il23)
-
4:33
il-17 family cytokines involved in psoriasis, m.a.x. tollenaere et al
-
2:23
how does ilumya work to treat psoriasis
-
39:56
advances in the management of allergic and inflammatory diseases
-
1:51
il-23s: psoriasis therapy overview
-
4:48
an insight into the management of cytopenias in mf